Download MendeleyDe Novo Design of Boron-Based Peptidomimetics as Potent Inhibitors of Human ClpP in the Presence of Human ClpX.
Tan, J., Grouleff, J.J., Jitkova, Y., Diaz, D.B., Griffith, E.C., Shao, W., Bogdanchikova, A.F., Poda, G., Schimmer, A.D., Lee, R.E., Yudin, A.K.(2019) J Med Chem 62: 6377-6390
- PubMed: 31187989
- DOI: https://doi.org/10.1021/acs.jmedchem.9b00878
- Primary Citation of Related Structures:
6N80 - PubMed Abstract:
Boronic acids have attracted the attention of synthetic and medicinal chemists due to boron's ability to modulate enzyme function. Recently, we demonstrated that boron-containing amphoteric building blocks facilitate the discovery of bioactive aminoboronic acids. Herein, we have augmented this capability with a de novo library design and a virtual screening platform modified for covalent ligands. This technique has allowed us to rapidly design and identify a series of α-aminoboronic acids as the first inhibitors of human ClpXP, which is responsible for the degradation of misfolded proteins.
Organizational Affiliation:
Davenport Research Laboratories, Department of Chemistry , University of Toronto , 80 St. George Street , Toronto , Ontario M5S 3H6 , Canada.
